Intravascular Bronchoalveolar Tumor

Prats, M.S.; Cáliz, C.; Sancho, F J; Cornudella, R.

doi:10.1159/000195878

Cited by 4 publications

(3 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Laboratory data revealed that alkaline phosphatase was increased in three patients and that two of them proved to have liver metastases. Gammaglobulinaemia was noticed only in two patients 13,14 …”

Section: Review Of the Literaturementioning

confidence: 98%

“…A Medline search was performed to collect data on previously published cases of PEH and 13 authors in Japan, Belgium and USA were contacted to obtain full patient data. In this review, we studied the data of 93 patients, 4–64 including our patient by Cox regression analysis using forward stepwise method (SPSS version 9, SPSS, Chicago, IL, USA) to identify the risk factors and the independent predictors of survival in patients with PEH.…”

Section: Review Of the Literaturementioning

confidence: 99%

“…Gammaglobulinaemia was noticed only in two patients. 13,14 Macroscopically, PEH was usually greyish-white or yellowish-white, firm, non-encapsulated, discrete nodule(s). In the literature, the tumour cells were microscopically similar to that described in the present patient.…”

Section: Review Of the Literaturementioning

confidence: 99%

See 2 more Smart Citations

Risk factors and independent predictors of survival in patients with pulmonary epithelioid haemangioendothelioma. Review of the literature and a case report

Amin

Hiroshima

Kokubo³

et al. 2006

Respirology

105

View full text Add to dashboard Cite

Pulmonary epithelioid haemangioendothelioma (PEH) is a rare pulmonary neoplasm. A patient with PEH with lymph node and pleural metastases that were discovered incidentally is described. An abnormal left upper lobe shadow was noticed on CXR in a 70-year-old woman during an assessment for the sudden onset of nausea and vomiting. Transbronchial lung biopsy did not provide a diagnosis. Lobectomy and lymph node resection were performed. The histological diagnosis of PEH was confirmed immunohistochemically by positive reactions to factor VIII-related antigen and CD34. Data on 93 patients with PEH including the present case report were analysed by Cox regression analysis using forward stepwise method to identify the risk factors, and the independent predictors of survival in patients with PEH. It revealed that male, symptomatic patients, presence of cough, haemoptysis, chest pain, multiple unilateral nodules, pleural effusion, metastases to more than one site and lymph node metastases were all significant risk factors for PEH (P<0.05). Symptomatic patients and presence of pleural effusion were the independent predictors of survival in patients with PEH.

show abstract

Section: Review Of the Literaturementioning

confidence: 98%

Section: Review Of the Literaturementioning

confidence: 99%

See 1 more Smart Citation

Risk factors and independent predictors of survival in patients with pulmonary epithelioid haemangioendothelioma. Review of the literature and a case report

Amin

Hiroshima

Kokubo³

et al. 2006

Respirology

105

View full text Add to dashboard Cite

show abstract

Pulmonary Vascular Tumors and Malformations

Thomas¹

2006

Pulmonary Vascular Disease

View full text Add to dashboard Cite

Pulmonary eosinophilia associated with montelukast

Franco

Artés

1999

Thorax

View full text Add to dashboard Cite

Antileukotriene drugs are new therapeutic agents that have recently been approved for the treatment of asthma. Several cases of eosinophilic conditions including ChurgStrauss syndrome have been reported to be associated with zafirlukast, a cysteinyl leukotriene type 1 receptor antagonist. So far no other leukotriene modifier has been associated with the syndrome. The case history is presented of a man with allergic rhinitis and asthma who had received intermittent pulse therapy with oral corticosteroids. Pulmonary eosinophilia developed while he was receiving treatment with montelukast, a chemically distinct cysteinyl leukotriene type 1 receptor antagonist. After discontinuation of montelukast therapy and administration of systemic corticosteroids the patient's symptoms reversed rapidly and there was prompt resolution of the pulmonary infiltrates. We believe that cysteinyl leukotriene type 1 receptor antagonists are safe and eVective drugs for most patients with asthma but caution is needed for those with more severe disease who require systemic corticosteroids, especially if they show characteristics of the atypical allergic diathesis seen in the prodromal phase of Churg-Strauss syndrome. (Thorax 1999;54:558-560) Keywords: montelukast; side eVects; pulmonary eosinophiliaThe antileukotriene drugs are new therapeutic agents which have recently been approved and are now available for the treatment of asthma in several countries. These drugs include one enzyme inhibitor of 5-lipoxygenase, zileuton, and three chemically distinct cysteinyl leukotriene type 1 receptor antagonists, zafirlukast, pranlukast and montelukast. As the use of these drugs increases, adverse events occurring at low frequency or in populations not examined in clinical trials may become manifest.2 Several cases of eosinophilic conditions including Churg-Strauss syndrome have been reported in patients who have been treated with zafirlukast. [2][3][4] No other leukotriene modifier has yet been associated with the syndrome.In this case report we describe an asthmatic patient in whom pulmonary eosinophilia developed while receiving montelukast therapy. Case reportA 26 year old man with a three year history of asthma had received treatment with salbutamol, nedocromil, theophylline, and beclomethasone. There was a five year history of allergic rhinitis with positive skin tests for house dust mite and cat dander. Because asthma symptoms were not well controlled, treatment was started with fluticasone 1000 µg daily and salmeterol twice a day. Allergen immunotherapy was also prescribed. Nonetheless, short courses of oral prednisone 40 mg or deflazacort 60 mg daily were required on several occasions to control asthma exacerbations. A decision was made to initiate treatment with montelukast at a dose of 10 mg daily in the evening. Treatment with fluticasone was continued.After approximately four months of treatment with montelukast the patient developed headache, malaise, myalgia, nasal congestion, and fever up to 39ºC. Oral cefuroxime and parac...

show abstract

Intravascular Bronchoalveolar Tumor

Cited by 4 publications

References 2 publications

Risk factors and independent predictors of survival in patients with pulmonary epithelioid haemangioendothelioma. Review of the literature and a case report

Risk factors and independent predictors of survival in patients with pulmonary epithelioid haemangioendothelioma. Review of the literature and a case report

Pulmonary Vascular Tumors and Malformations

Pulmonary eosinophilia associated with montelukast

Contact Info

Product

Resources

About